Overview

Dopaminergic Therapy for Anhedonia - 2

Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks. Participants will complete lab tests, medical and psychiatric assessments, motivation and motor tasks, and MRI scans as part of the study. The total length of participation is approximately 10 to 12 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Emory University
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Carbidopa
Carbidopa, levodopa drug combination
Levodopa